| アブストラクト | BACKGROUND: Combining immunotherapy with targeted therapy represents a promising trajectory for cancer treatment; however, safety profiles remain insufficient. This study aimed to characterize adverse events associated with immune-targeted regimens in hepatocellular carcinoma (HCC). METHODS: This study used Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), and Bayesian Confidence Propagation Neural Network (BCPNN) to detect signals of adverse events based on data from FDA Adverse Event Reporting System. RESULTS: Signals of fulminant type-1 diabetes mellitus (ROR = 13.3, PRR = 13.2, IC = 3.7), myositis (8.5, 8.3, 3.1), encephalitis (8.4, 8.3, 3.0), and myocarditis (7.3, 7.2, 2.8) were identified in atezolizumab+bevacizumab. Immune-mediated hepatitis (5.6, 5.1, 2.4), hepatic encephalopathy (3.3, 3.0, 1.6), and uppergastrointestinal haemorrhage (4.3, 4.2, 2.1) were associated with pembrolizumab+lenvatinib. Signals of gastrointestinal haemorrhage (5.1, 4.8, 2.3) and malignant neoplasm progression (2.9, 2.7, 1.4) were in patients using atezolizumab+cabozantinib. CONCLUSION: This study delineated distinct profiles of adverse events associated with immunotargeted therapies, which serves as a critical reference for risk assessment and therapeutic selection. Though atezolizumab plus bevacizumab is recommended as first-line treatment for advanced HCC, potential severe immune-mediated adverse events affecting multiple organs suggested the importance of clinical vigilance. Extrapolation of pembrolizumab+lenvatinib and atezolizumab+cabozantinib from other cancers to HCC warrants caution in consideration of the associated bleeding risks and hepatic complications. |
|---|
| ジャーナル名 | Journal of gastrointestinal cancer |
|---|
| Pubmed追加日 | 2026/7/16 |
|---|
| 投稿者 | Song, Menghuan; Feng, Tianyue; Deng, Ning; Yang, Zhirong; Lai, Yunfeng; Ung, Carolina Oi Lam; Hu, Hao |
|---|
| 組織名 | State Key Laboratory of Mechanism and Quality of Chinese Medicine, University of;Macau, Macao, SAR, China.;Centre for Pharmaceutical Regulatory Sciences, University of Macau, Macao, SAR,;China.;Department of Computational Biology and Medical Big Data, Shenzhen University of;Advanced Technology, Shenzhen, China.;Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen,;School of Public Health and Management, Guangzhou University of Chinese Medicine,;Guangzhou, China.;Macau, Macao, SAR, China. carolinaung@um.edu.mo.;China. carolinaung@um.edu.mo.;Department of Public Health and Medicinal Administration, Faculty of Health;Sciences, University of Macau, Macao, SAR, China. carolinaung@um.edu.mo.;Macau, Macao, SAR, China. haohu@um.edu.mo.;China. haohu@um.edu.mo.;Sciences, University of Macau, Macao, SAR, China. haohu@um.edu.mo. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/42461453/ |
|---|
